

Maximizing cost-effectiveness by conjugating modifications for clinical application of innovative nucleic acid drugs

Principal Investigator

Department of Medical Data Science, Graduate School of Medicine, Osaka University

Professor Hideshi ISHII

Project Outline

- This project targets refractory gastrointestinal cancers that do not respond to conventional treatments.
- We are developing nucleic acid drugs as a part of an advanced seed project at Osaka University.
- Nucleic acid drugs have attracted attention for their potential for precise control.
- This project targets cancer stem cells and their microenvironments with nucleic acid drugs.
- Basic nonclinical testing is already underway, and patenting is complete.
- Development is expected to accelerate under cooperation with drug manufacturers.


■ Strategy:

"Differentiation" is the key to success in the global anticancer drugs market, which is expected to reach 500 billion dollars in 2020.

This seed project of ours represents a worldfirst concept.

In addition, we use a special method for optimizing clinical applications.

We have patented this basic seed and are building on our success.



The world's first conjugate-modified nucleic acid drug for treating cancer. The pinpoint attack surpasses existing treatments, using a strategy that matches the tumors' microenvironments. Basic preclinical tests completed.